Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Allergy and Clinical Immunology: In Practice

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaip.2016.12.001PMID 28110056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.

  2017influential reference
• Successful Desensitization to Cetuximab in a Patient With a Positive Skin Test to Cetuximab and Specific IgE to Alpha-gal.

  2016cited by this paper
• Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.

  2016influential reference
• Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization.

  2016influential reference
• Human IgE-independent systemic anaphylaxis.

  2016cited by this paper
• Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels

  2016cited by this paper
• Rituximab Desensitization in Pediatric Patients: Results of a Case Series

  2016cited by this paper
• Characteristics of Skin Lesions Associated With AntiTumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

  2016cited by this paper
• Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.

  2016influential reference
• Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions

  2016cited by this paper
• CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

  2016cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

  2015influential reference
• Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

  2015cited by this paper
• Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients.

  2015influential reference
• Adverse reactions to infliximab and the outcome of desensitization.

  2015influential reference
• The alpha-gal story: lessons learned from connecting the dots.

  2015cited by this paper
• Infliximab-Related Infusion Reactions: Systematic Review

  2015influential reference
• IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment

  2015cited by this paper
• Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization

  2015influential reference
• Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

  2015cited by this paper
• Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.

  2015cited by this paper
• Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab.

  2015cited by this paper
• Rituximab-induced serum sickness: A systematic review.

  2015influential reference
• Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry

  2015cited by this paper
• Ofatumumab for treating chronic lymphocytic leukemia: a safety profile

  2015cited by this paper
• Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.

  2014cited by this paper
• Miscellaneous adverse events with biologic agents (excludes infection and malignancy).

  2014influential reference
• International Consensus on drug allergy

  2014cited by this paper
• The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

  2014influential reference
• Successful rapid tocilizumab desensitization in a patient with Still disease.

  2014influential reference
• Successful desensitization to brentuximab vedotin after anaphylaxis.

  2014cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions

  2014cited by this paper
• Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis.

  2014cited by this paper
• Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

  2014influential reference
• Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

  2014cited by this paper
• Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

  2014cited by this paper
• Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

  2013influential reference
• Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease

  2013cited by this paper
• Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab

  2013influential reference
• Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

  2012cited by this paper
• Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab

  2012influential reference
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose.

  2012cited by this paper
• Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

  2011cited by this paper
• American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.

  2011cited by this paper
• The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose.

  2011cited by this paper
• Successful desensitization of three patients with hypersensitivity reactions to omalizumab.

  2011cited by this paper
• Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer

  2011cited by this paper
• Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

  2010cited by this paper
• The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• The safety and interpretability of skin tests with omalizumab.

  2010cited by this paper
• Drug allergy: an updated practice parameter.

  2010cited by this paper
• The safety of infliximab infusions in the community setting.

  2010cited by this paper
• Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions

  2010cited by this paper
• Mammalian meat-induced anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab.

  2009cited by this paper
• A desensitization protocol for the mAb cetuximab.

  2009cited by this paper
• Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.

  2009cited by this paper
• Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

  2009cited by this paper
• Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.

  2009cited by this paper
• Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose.

  2009cited by this paper
• Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.

  2009influential reference
• Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.

  2008cited by this paper
• Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab.

  2008cited by this paper
• Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Injection site reactions to TNF-alpha blocking agents with positive skin tests.

  2008cited by this paper
• Bevacizumab 5 mg/kg can be infused safely over 10 minutes.

  2007cited by this paper
• Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

  2007cited by this paper
• High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

  2007cited by this paper
• Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases

  2007cited by this paper
• Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.

  2007cited by this paper
• American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.

  2007cited by this paper
• Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease.

  2007cited by this paper
• Injection site reactions to TNF‐α blocking agents with positive skin tests

  2007cited by this paper
• Serum sickness-like reactions in patients receiving intravenous infliximab.

  2006cited by this paper
• Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

  2006cited by this paper
• Clinical features and severity grading of anaphylaxis.

  2004cited by this paper
• The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience

  2003influential reference
• Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

  2003cited by this paper
• Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern.

  2002cited by this paper
• Stevens-Johnson syndrome after treatment with rituximab.

  2002cited by this paper
• The debate over diagnostic accuracy in melanoma: dermatologists or general practitioners?

  2002cited by this paper
• Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

  2001influential reference
• Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer

  2001cited by this paper
• Meperidine Decreases the Shivering Threshold Twice as Much as the Vasoconstriction Threshold

  1997cited by this paper
• Extended Report

  year unknowncited by this paper

• Successful Resuscitation of Anaphylactic Shock With Central Nervous System Dysfunction in a Patient on Multiple Antihypertensive Therapies: A Case Report and Literature Review

  2026cites this paper
• Oral glucocorticoid premedication for preventing infusion-related reactions to rituximab in rheumatoid arthritis.

  2026cites this paper
• Safety and Outcomes of Rapid Drug Desensitization to Various Biologic Agents: A Multidisciplinary Experience

  2026cites this paper
• Prevalence and Management of Immediate Adverse Reactions to Chemotherapy in Breast Cancer Patients: A Retrospective Study

  2025cites this paper
• [Non-allergic immediate hypersensitivity to Brentuximab vedotin in pediatrics: usefulness of skin testing to guide provocation testing].

  2025cites this paper
• Implementation of Rapid Drug Desensitization in Antineoplastic Drug Therapy in Denmark Using One‐Bag Protocols

  2025cites this paper
• Recent Insights into the Epidemiology and Management of Anaphylaxis

  2025cites this paper
• Hypersensitivity reactions to chemotherapy and biologics: Outcomes and safety of 927 desensitization in Mexico.

  2025cites this paper
• Desensitization to Tocilizumab in a Patient With Juvenile Idiopathic Arthritis

  2025cites this paper
• The value of skin testing with tumor necrosis factor-inhibitors in patients with local and systemic hypersensitivity reactions.

  2025cites this paper
• Case Report: Successful Drug Desensitization to Ustekinumab in an Adult Patient with Crohn’s Disease

  2025cites this paper
• Management of infusion-related reactions in cancer therapy: strategies and challenges

  2024cites this paper
• Drug allergy

  2024cites this paper
• Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies

  2024cites this paper
• Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab

  2024cites this paper
• Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals, 2024 update

  2024cites this paper
• Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies.

  2024cites this paper
• Immediate Hypersensitivity Reactions to Biologic Drugs in Children with Inflammatory Bowel Diseases

  2024cites this paper
• Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients

  2024influential citation
• Implementation of an Accelerated Infusion Protocol (90-Minute Infusion) of Rituximab and Its Safety in Patients With Autoimmune Rheumatic Diseases at a Tertiary Veterans Affairs Center

  2024cites this paper
• Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel

  2024cites this paper
• Systemic allergic reaction to galcanezumab (emgality): a case report

  2024influential citation
• Recall Urticaria with Infusion of Agalsidase Beta.

  2023cites this paper
• Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions

  2023cites this paper
• Acute low back pain as infusion-related reaction to monoclonal antibodies

  2023cites this paper
• Interleukin-6 as a biomarker of hypersensitivity reactions in chemotherapeutics and monoclonal antibodies

  2023cites this paper
• T cell‐and non T cell‐mediated delayed hypersensitivity to dupilumab

  2023cites this paper
• Anaphylaxis to Drugs, Biological Agents, and Vaccines.

  2022cites this paper
• Successful Rapid Drug Desensitization with A Modified Protocol To Alemtuzumab in A Multiple Sclerosis Patient with Severe Immediate-Type Hypersensitivity Reaction.

  2022cites this paper
• Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab

  2022cites this paper
• Utilizing Biologics in Drug Desensitization

  2022cites this paper
• IL-6 and Cytokine Release Syndrome: a new understanding in drug hypersensitivity reactions.

  2022cites this paper
• Hypersensitivity reactions to biologics in children

  2022cites this paper
• Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases

  2022cites this paper
• A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice.

  2022cites this paper
• Drug Allergy: A 2022 Practice Parameter Update.

  2022cites this paper
• Hypersensitivity reactions to multiple biologicals in a pediatric patient with severe persistent asthma

  2022cites this paper
• Hypersensitivity Reactions to Monoclonal Antibodies: New Approaches

  2022cites this paper
• Abordagem de doentes com suspeita de hipersensibilidade a anticorpos monoclonais: Experiência de um serviço

  2022influential citation
• Safety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents

  2022cites this paper
• Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement

  2022cites this paper
• Immediate Adverse Reactions to Horse Anti-Thymocyte Globulin: a 10-year Single Center Experience.

  2022cites this paper
• Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

  2022cites this paper
• The Who, What, Where, When, Why, and How of Drug Desensitization.

  2022cites this paper
• Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.

  2022cites this paper
• Cancer Immunotherapies: What the Perioperative Physician Needs to Know

  2022cites this paper
• Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe

  2022cites this paper
• Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases

  2022cites this paper
• Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma

  2022cites this paper
• CASE Successful Rapid Drug Desensitization with A Modified Protocol To Alemtuzumab in A Multiple Sclerosis Patient with Severe Immediate-Type Hypersensitivity Reaction

  2022influential citation
• Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis

  2021cites this paper
• A long-term open-label safety study of galcanezumab in Japanese patients with migraine

  2021cites this paper
• Skin testing and drug challenge in the evaluation of drug hypersensitivity reactions.

  2021cites this paper
• Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization.

  2021cites this paper
• Toxicity of Immunotherapeutic Agents.

  2021cites this paper
• Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017

  2021cites this paper
• Evaluation of Hypersensitivity Reactions in Pediatric Patients Using Biological Drugs

  2021cites this paper
• Hypersensitivity reactions to biologicals: An EAACI position paper

  2021cites this paper
• Recall Injection-Site Reactions After Treatment With Anakinra.

  2021cites this paper
• Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection

  2021cites this paper
• Dermpath and Clinic: How to manage adverse reactions to biological agents

  2021cites this paper
• Hypersensitivity and Immune-related Adverse Events in Biologic Therapy

  2021cites this paper
• Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors

  2021cites this paper
• Induction de tolérance aux médicaments

  2021cites this paper
• Successful desensitization to high dose rituximab for a child with nephrotic syndrome – The first report in the literature

  2021cites this paper
• Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

  2021cites this paper
• A critical evaluation of crizanlizumab for the treatment of sickle cell disease

  2021influential citation
• Hypersensitivity Reactions to Biologicals: from Bench to Bedside

  2020cites this paper
• Hypersensitivity to Rituximab in Children

  2020cites this paper
• Non-IgE adverse reactions to biologics.

  2020cites this paper
• The Prevalence of Hypersensitivity Reactions to Antirheumatic Biological Agents and Results of the Skin Tests: Experience of a Tertiary Referral Allergy Center in Turkey

  2020influential citation
• BIOLOGICAL TREATMENTS IN ALLERGY: PRESCRIBING PATTERNS AND MANAGEMENT OF HYPERSENSITIVITY REACTIONS.

  2020cites this paper
• Fixed drug eruption secondary to adalimumab

  2020cites this paper
• Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs.

  2020cites this paper
• “Cytokine storm”, not only in COVID-19 patients. Mini-review

  2020cites this paper
• Skin tests in the diagnosis of adverse drug reactions: a systematic review.

  2020cites this paper
• Rituximab Hypersensitivity: From Clinical Presentation to Management

  2020cites this paper
• Past, Present, and Future of Anticancer Nanomedicine

  2020cites this paper
• Sub-visible Particles in IVIg Formulations Activate Complement in Human Serum.

  2020cites this paper
• Anaphylaxis.

  2020influential citation
• Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

  2020cites this paper
• Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals

  2020cites this paper
• Hypersensitivity Reactions to Monoclonal Antibodies in Children

  2020influential citation
• Rapid Desensitization to antineoplastic drugs in an outpatient Immunoallergology Clinic: outcomes and risk factors.

  2020cites this paper
• Children with reported penicillin allergy: Public health impact and safety of delabeling.

  2020cites this paper
• Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

  2020cites this paper
• Toxicities of novel therapies for hematologic malignancies

  2020cites this paper
• Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients.

  2020cites this paper
• Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

  2019cites this paper
• Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System

  2019cites this paper
• Protocols for drug allergy desensitization in children

  2019cites this paper
• Update on Desensitization

  2019cites this paper
• Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

  2019cites this paper
• The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents.

  2019cites this paper
• Biologics and anaphylaxis.

  2019cites this paper
• Recent developments in drug hypersensitivity in children

  2019cites this paper
• Hypersensitivity to Monoclonal Antibodies used for Cancer and Inflammatory/Connective Tissue Diseases.

  2019cites this paper
• Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases.

  2019cites this paper
• Chemotherapy and Biologic Drug Allergy

  2019cites this paper
• Pediatric Drug Hypersensitivity

  2019cites this paper